股票代码：002817 股票简称：黄山胶囊 编号：2023-001 投资者关系活动类 □特定对象调研 □分析师会议 别 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人 线上参与黄山胶囊 2022 年度网上业绩说明会的投资者 员姓名 时间 2023 年 05 月 10 日（星期三）下午 15:00-17:00 地点 "黄山胶囊投资者关系"微信小程序 董事、总经理：余超彪先生 上市公司接待人员 独立董事：沙风先生 姓名 副总经理：叶松林先生 副总经理：楚振华先生 财务总监：刘清科先生 副总经理、董事会秘书：张文政先生 1、问：现阶段来看，公司主要发展战略及重心是什么 答：尊敬的投资者您好！公司围绕"打造国内领先的医药 科技服务平台"这一长期目标。依托胶囊主营业务，深入 实施创新驱动发展战略，加大研发投入，加快设备更新和 投资者关系活动主 技术改造，持续提升生产车间智能化水平，进一步释放产 要内容介绍 能；加强技术合作与攻关，加大产品创新力度，着力提升 植物胶囊等新产品新工艺的研究，培育新的利润增长点。 继续深入推进产业结构布局优化，深化与战略客 ...

安徽黄山胶囊股份有限公司 2023 年第一季度报告 证券代码：002817 证券简称：黄山胶囊 公告编号：2023-014 安徽黄山胶囊股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 安徽黄山胶囊股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 143,226,804.73 | 101,310,277.27 | 41.37% | | 归属于上市公司股东 ...

Financial Performance - The company's operating revenue for 2022 was ¥428,318,791.71, representing a 12.75% increase compared to ¥379,891,008.70 in 2021[23] - The net profit attributable to shareholders for 2022 was ¥60,850,372.05, a 6.97% increase from ¥56,887,811.36 in 2021[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51,050,352.05, up 5.69% from ¥48,301,265.66 in the previous year[23] - The total assets at the end of 2022 were ¥1,037,692,058.04, down 1.53% from ¥1,053,820,293.60 at the end of 2021[23] - The net assets attributable to shareholders at the end of 2022 were ¥853,758,112.73, an increase of 5.44% from ¥809,694,572.19 at the end of 2021[23] - The basic earnings per share for 2022 were ¥0.20, a 5.26% increase from ¥0.19 in 2021[23] - The diluted earnings per share for 2022 were also ¥0.20, reflecting the same increase of 5.26% from the previous year[23] - The weighted average return on equity for 2022 was 7.34%, slightly up from 7.25% in 2021[23] Cash Flow - The net cash flow from operating activities was ¥83,016,820.72, a decrease of 3.57% from ¥86,089,406.99 in 2021[23] - Operating cash inflow increased by 10.09% to ¥391,715,445.37, while operating cash outflow rose by 14.45% to ¥308,698,624.65[61] - Net cash flow from operating activities decreased by 3.57% to ¥83,016,820.72[61] - Investment cash inflow surged by 258.65% to ¥545,466,959.68, while investment cash outflow increased by 204.74% to ¥559,132,194.23[61] - Net cash flow from investment activities improved by 56.47% to -¥13,665,234.55[62] - Cash and cash equivalents decreased by 124.69% to -¥25,285,572.34, primarily due to reduced financing cash flow[62] Revenue Breakdown - The company's total revenue for Q1 2022 was approximately CNY 101.31 million, with a peak in Q4 2022 at CNY 127.14 million, indicating a quarterly fluctuation of 25.3%[27] - Net profit attributable to shareholders for Q2 2022 was CNY 17.55 million, while Q4 2022 saw a decline to CNY 12.75 million, reflecting a decrease of 27.5%[27] - The sales of gel capsules accounted for 79.17% of total revenue, with a revenue of ¥339,080,226.02, up 10.88% from ¥305,805,926.12 in 2021[50] - Domestic sales reached ¥397,971,632.29, making up 92.91% of total revenue, while international sales surged by 157.43% to ¥30,347,159.42, representing 7.09% of total revenue[50] Research and Development - Research and development investment amounted to 14.98 million yuan, with 8 patent applications filed, including 3 invention patents[47] - R&D investment rose by 11.47% to ¥14,980,970.94, accounting for 3.50% of operating revenue[59] - The company has initiated several new product development projects, including hydroxypropyl methylcellulose hollow capsules, aiming for annual sales of 4 billion pieces[58] - Research and development expenses rose by 11.47% to ¥14,980,970.94 in 2022, compared to ¥13,439,131.79 in 2021[58] Market Strategy - The pharmaceutical industry is transitioning towards high-quality development, with a focus on product innovation and international expansion as outlined in the "14th Five-Year Plan" for the pharmaceutical industry[33] - The company is enhancing brand promotion in the traditional Chinese medicine sector to adapt to market changes and maintain healthy growth[34] - The company aims to enhance its competitive advantage through continuous investment in technology research and development, aiming to become a leading pharmaceutical technology service platform in China[45] - The company plans to optimize its industrial structure and expand international market presence to overcome development bottlenecks[74] - The company is expanding its human resources management to address the potential mismatch between talent supply and business growth needs[77] Governance and Compliance - The company held three shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[81] - The company maintains independent operations from its controlling shareholder, ensuring no interference in decision-making[85] - The company has established a complete and independent financial accounting system, allowing for autonomous financial decision-making[87] - The company has established rules for related party transactions to ensure they follow market principles[89] - The company conducted a self-assessment of its governance structure, finding it compliant with relevant laws and regulations, with no major defects affecting operations[135] Shareholder Information - The company plans to distribute a cash dividend of ¥0.6 per 10 shares, totaling approximately ¥17,945,908.20 based on 299,098,170 shares[4] - The company reported a cash dividend of RMB 17,945,890.20 for the fiscal year, which represents 29.49% of the distributable profit of RMB 411,140,417.21[124] - The total number of shares increased from 213,641,550 to 299,098,170 after a capital reserve conversion, resulting in a 40.00% increase in total shares[180] - The largest shareholder, Shandong Lutai Holding Group, holds 29.99% of the shares, totaling 89,699,541 shares[187] Employee Management - The total number of employees at the end of the reporting period was 681, with 493 in production, 30 in sales, 81 in technical roles, 7 in finance, and 70 in administration[118] - The company implemented a performance-oriented salary system, enhancing employee motivation and retention through various incentive mechanisms[119] - The training completion rate for the year was 100%, with 429 frontline employees trained in SOP and professional knowledge, and 59 new employees receiving pre-job skills training[121] - The company has established a comprehensive training management system, combining internal and external training to enhance employee skills[121] Environmental and Social Responsibility - The company invested in supercritical CO2 heating and cooling systems and catalytic combustion systems, effectively reducing energy consumption and emissions[136] - The company donated 154,500 yuan to social welfare activities, including blood donation and support for disadvantaged employees[137] - The company emphasizes the importance of timely and accurate information disclosure to protect the rights of shareholders and creditors[134] Future Outlook - The company’s future outlook remains positive, with expectations of continued growth in revenue and market share[98] - The company has set a revenue target of 1 billion RMB for the next fiscal year, indicating a growth expectation of 25%[105] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[105] - The company aims to strengthen its competitive position in the industry through potential mergers and acquisitions, although no specific targets were mentioned[98]

证券代码：002817 证券简称：黄山胶囊 安徽黄山胶囊股份有限公司投资者关系活动记录表 编号：2019-001 | --- | --- | --- | |-------------------------|-----------------------------|------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 ■业绩说明会 | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 参与单位名称及 人员姓名 | 投资者 | | | | | | | 时间 | 2019 年 5 月 6 日 | 15:00-17:00 | | 地点 | " 全景•路演天下"（ | http://rs.p5w.net ） | | 上市公司接待人 | 董事长 余春明 | | | 员姓名 | 总经理 余超彪 | | | | 董事会秘书 项先理 | | | | 财务负责人 汪红时 | | | | 独立董事 曲凯 | | | | 保荐代表人 高震 | ...

Group 1: Company Overview and Strategy - Anhui Huangshan Capsule Co., Ltd. aims to become a leading pharmaceutical technology service platform in China [1][4] - The company focuses on scientific budgeting and refined management to align expenses with business development [4] Group 2: Product Information - The main product, gelatin hollow capsules, is primarily used for drugs sensitive to light and moisture, enhancing bioavailability compared to tablets [5] - The market for gelatin hollow capsules remains dominant, with HPMC plant-based capsules as a supplementary option due to higher costs and regulatory restrictions [4][5] Group 3: Financial Performance and Market Position - The company reported a significant portion of revenue from gelatin hollow capsules, indicating a concentrated revenue stream [6][7] - The company has established a good reputation among domestic pharmaceutical and health food enterprises, maintaining a stable customer base [7] Group 4: Overseas Market Expansion - The company has made progress in expanding into the North American market, including the establishment of a subsidiary in the U.S. and exporting five batches of capsules [7][9] - Future overseas sales are expected to grow, driven by increased demand due to the COVID-19 pandemic [9][13] Group 5: Risks and Challenges - Potential risks in overseas expansion include rising shipping costs, exchange rate fluctuations, and instability in overseas client operations due to the pandemic [6][13] - The company is aware of the challenges posed by the international political environment and is prepared to address them [13] Group 6: Research and Development - The company plans to increase investment in R&D, focusing on plant-based capsules and enteric-coated gelatin capsules to diversify its product offerings [8][10] - Current production capacity is projected to exceed 40 billion capsules, supported by the completion of a digital workshop [11]

证券代码：002817 证券简称：黄山胶囊 安徽黄山胶囊股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-------------------------|-------------------------------------------------|--------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | 业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | □现场参观 | 其他（ 2022 年安徽辖区上市公司 | | | | 投资者网上集体接待日活动） | | 参与单位名称及 人员姓名 | 线上参与 2022 动的投资者 | 年安徽辖区上市公司投资者网上集体接待日活 | | 时间 2022 | 年 09 月 07 日 | 16:00-17:30 | | 地点 | "全景•路演"（ | http://rs.p5w.net ） | | | | | | 上市公司接待人 员姓名 | ...

安徽黄山胶囊股份有限公司 2022 年第三季度报告 证券代码：002817 证券简称：黄山胶囊 公告编号：2022-036 安徽黄山胶囊股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 93,656,298.81 | 13.10% | 301,178,173.56 | 8.30% | | 归属于上市公司股东 | 16,583,398.01 | 3.32% | 48,099,259.10 ...

证券代码：002817 证券简称：黄山胶囊 公告编号：2022-028 安徽黄山胶囊股份有限公司 关于参加安徽辖区上市公司 2022 年 投资者集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，安徽黄山胶囊股份有限公司（以下简称 "公司"或"本公司"）将参加由安徽证监局指导、安徽上市公司协会与深圳市 全景网络有限公司联合举办的"2022年安徽辖区上市公司投资者集体接待日活 动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP， 参与本次互动交流，活动时间为2022年9月7日（周三）16：00-17：30。届时公 司高管将在线就公司2022年半年度报告中的公司业绩、公司治理、发展战略、经 营状况和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大 投资者踊跃参与。 特此公告。 安徽黄山胶囊股份有限公司董事会 2022年09月05日 ...

安徽黄山胶囊股份有限公司 2022 年半年度报告全文 安徽黄山胶囊股份有限公司 2022 年半年度报告 【2022 年 8 月 25 日】 1 安徽黄山胶囊股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人余超彪、主管会计工作负责人董雪及会计机构负责人(会计主 管人员)董雪声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来计划、业绩预测等方面的内容，均不构成本公司 对投资者的实质承诺，敬请投资者注意投资风险。 本公司请投资者认真阅读本报告全文，公司已在本报告"第三节管理层 讨论与分析"中"十、公司面临的风险和应对措施"部分，对可能面临的风 险进行了描述，敬请投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 安徽黄山胶囊股份有限公司 2022 年半年度报告全文 5 释义项 指 释义内容 黄山胶囊、发行人、公司、本公司、 股份公司 ...

安徽黄山胶囊股份有限公司 2022 年第一季度报告全文 证券代码：002817 证券简称：黄山胶囊 公告编号：2022-020 安徽黄山胶囊股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 (二)非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 101,310,277.27 | 104,095,453.39 | -2.68% | | ...